270 related articles for article (PubMed ID: 25645011)
1. The delay time in sickle cell disease after 40 years: A paradigm assessed.
Ferrone FA
Am J Hematol; 2015 May; 90(5):438-45. PubMed ID: 25645011
[TBL] [Abstract][Full Text] [Related]
2. Quantitative prediction of erythrocyte sickling for the development of advanced sickle cell therapies.
Lu L; Li Z; Li H; Li X; Vekilov PG; Karniadakis GE
Sci Adv; 2019 Aug; 5(8):eaax3905. PubMed ID: 31457104
[TBL] [Abstract][Full Text] [Related]
3. New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo?
Oder E; Safo MK; Abdulmalik O; Kato GJ
Br J Haematol; 2016 Oct; 175(1):24-30. PubMed ID: 27605087
[TBL] [Abstract][Full Text] [Related]
4. Exposure of blood from patients with sickle cell disease to air changes the morphological, oxygen-binding, and sickling properties of sickled erythrocytes.
Obata K; Mattiello J; Asakura K; Ohene-Frempong K; Asakura T
Am J Hematol; 2006 Jan; 81(1):26-35. PubMed ID: 16369974
[TBL] [Abstract][Full Text] [Related]
5. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease.
Oksenberg D; Dufu K; Patel MP; Chuang C; Li Z; Xu Q; Silva-Garcia A; Zhou C; Hutchaleelaha A; Patskovska L; Patskovsky Y; Almo SC; Sinha U; Metcalf BW; Archer DR
Br J Haematol; 2016 Oct; 175(1):141-53. PubMed ID: 27378309
[TBL] [Abstract][Full Text] [Related]
6. Targeting HbS Polymerization.
Ferrone FA
Semin Hematol; 2018 Apr; 55(2):53-59. PubMed ID: 30616807
[TBL] [Abstract][Full Text] [Related]
7. Sickle cell vaso-occlusion.
Fabry ME; Kaul DK
Hematol Oncol Clin North Am; 1991 Jun; 5(3):375-98. PubMed ID: 1864816
[TBL] [Abstract][Full Text] [Related]
8. Delay time of hemoglobin S polymerization prevents most cells from sickling in vivo.
Mozzarelli A; Hofrichter J; Eaton WA
Science; 1987 Jul; 237(4814):500-6. PubMed ID: 3603036
[TBL] [Abstract][Full Text] [Related]
9. Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors.
Okam MM; Ebert BL
Expert Rev Hematol; 2012 Jun; 5(3):303-11. PubMed ID: 22780210
[TBL] [Abstract][Full Text] [Related]
10. Established and experimental treatments for sickle cell disease.
De Franceschi L; Corrocher R
Haematologica; 2004 Mar; 89(3):348-56. PubMed ID: 15020275
[TBL] [Abstract][Full Text] [Related]
11. In vitro exposure to hydroxyurea reduces sickle red blood cell deformability.
Huang Z; Louderback JG; King SB; Ballas SK; Kim-Shapiro DB
Am J Hematol; 2001 Jul; 67(3):151-6. PubMed ID: 11391710
[TBL] [Abstract][Full Text] [Related]
12. Polymerization of sickle cell hemoglobin at arterial oxygen saturation impairs erythrocyte deformability.
Green MA; Noguchi CT; Keidan AJ; Marwah SS; Stuart J
J Clin Invest; 1988 Jun; 81(6):1669-74. PubMed ID: 3384944
[TBL] [Abstract][Full Text] [Related]
13. The role of hydroxyurea in sickle cell disease.
Halsey C; Roberts IA
Br J Haematol; 2003 Jan; 120(2):177-86. PubMed ID: 12542474
[No Abstract] [Full Text] [Related]
14. Non-uniformity of intracellular polymer formation in sickle erythrocytes: possible correlation with severity of hemolytic anemia.
Noguchi CT; Schechter AN
Am J Pediatr Hematol Oncol; 1984; 6(1):46-50. PubMed ID: 6711762
[TBL] [Abstract][Full Text] [Related]
15. Kinetics of increased deformability of deoxygenated sickle cells upon oxygenation.
Huang Z; Hearne L; Irby CE; King SB; Ballas SK; Kim-Shapiro DB
Biophys J; 2003 Oct; 85(4):2374-83. PubMed ID: 14507701
[TBL] [Abstract][Full Text] [Related]
16. Rapid and reproducible characterization of sickling during automated deoxygenation in sickle cell disease patients.
Rab MAE; van Oirschot BA; Bos J; Merkx TH; van Wesel ACW; Abdulmalik O; Safo MK; Versluijs BA; Houwing ME; Cnossen MH; Riedl J; Schutgens REG; Pasterkamp G; Bartels M; van Beers EJ; van Wijk R
Am J Hematol; 2019 May; 94(5):575-584. PubMed ID: 30784099
[TBL] [Abstract][Full Text] [Related]
17. Intracellular polymerization of sickle hemoglobin: disease severity and therapeutic goals.
Noguchi CT; Rodgers GP; Schechter AN
Prog Clin Biol Res; 1987; 240():381-91. PubMed ID: 3615501
[TBL] [Abstract][Full Text] [Related]
18. Should we still be focused on red cell hemoglobin F as the principal explanation for the salutary effect of hydroxyurea in sickle cell disease?
Segel GB; Simon W; Lichtman MA
Pediatr Blood Cancer; 2011 Jul; 57(1):8-9. PubMed ID: 21480473
[No Abstract] [Full Text] [Related]
19. Effect of piracetam on sickle erythrocytes and sickle hemoglobin.
Asakura T; Ohnishi ST; Adachi K; Ozguc M; Hashimoto K; Devlin MT; Schwartz E
Biochim Biophys Acta; 1981 May; 668(3):397-405. PubMed ID: 7236716
[TBL] [Abstract][Full Text] [Related]
20. Exercise limitation, exercise testing and exercise recommendations in sickle cell anemia.
Connes P; Machado R; Hue O; Reid H
Clin Hemorheol Microcirc; 2011; 49(1-4):151-63. PubMed ID: 22214686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
